JP2024516969A - 代謝性疾患の治療のためのラクトイルアミノ酸 - Google Patents

代謝性疾患の治療のためのラクトイルアミノ酸 Download PDF

Info

Publication number
JP2024516969A
JP2024516969A JP2023564664A JP2023564664A JP2024516969A JP 2024516969 A JP2024516969 A JP 2024516969A JP 2023564664 A JP2023564664 A JP 2023564664A JP 2023564664 A JP2023564664 A JP 2023564664A JP 2024516969 A JP2024516969 A JP 2024516969A
Authority
JP
Japan
Prior art keywords
lac
phe
lactoyl
subject
exercise
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564664A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516969A5 (https=
JPWO2022235557A5 (https=
Inventor
ジョナサン・ロング
ベロニカ・リー
スティーブン・バニク
ヨン・シュイ
ヤン・ホー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of JP2024516969A publication Critical patent/JP2024516969A/ja
Publication of JP2024516969A5 publication Critical patent/JP2024516969A5/ja
Publication of JPWO2022235557A5 publication Critical patent/JPWO2022235557A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2023564664A 2021-05-04 2022-05-02 代謝性疾患の治療のためのラクトイルアミノ酸 Pending JP2024516969A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163183868P 2021-05-04 2021-05-04
US63/183,868 2021-05-04
PCT/US2022/027261 WO2022235557A1 (en) 2021-05-04 2022-05-02 Lactoyl amino acids for the treatment of metabolic disease

Publications (3)

Publication Number Publication Date
JP2024516969A true JP2024516969A (ja) 2024-04-18
JP2024516969A5 JP2024516969A5 (https=) 2025-04-24
JPWO2022235557A5 JPWO2022235557A5 (https=) 2025-04-24

Family

ID=83932803

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564664A Pending JP2024516969A (ja) 2021-05-04 2022-05-02 代謝性疾患の治療のためのラクトイルアミノ酸

Country Status (7)

Country Link
US (1) US20240189266A1 (https=)
EP (1) EP4313297A4 (https=)
JP (1) JP2024516969A (https=)
KR (1) KR20240006050A (https=)
CN (1) CN117769414A (https=)
AU (1) AU2022271191A1 (https=)
WO (1) WO2022235557A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240122888A1 (en) * 2022-10-03 2024-04-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of phenylalanine and lactate
CN116035217B (zh) * 2022-12-23 2023-08-04 暨南大学 一种具有减肥减脂作用的组合物与应用
WO2024192165A1 (en) * 2023-03-14 2024-09-19 The Board Of Trustees Of The Leland Stanford Junior University N-beta-hydroxybutyryl-amino acids and related compositions and methods
WO2025072489A2 (en) * 2023-09-27 2025-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use
WO2025184353A1 (en) * 2024-03-01 2025-09-04 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating metabolic disorders
CN118795011B (zh) * 2024-06-28 2025-01-21 合肥工业大学 一种用于细胞代谢产物n-l-乳酰-l-苯丙氨酸的快速检测方法
CN119350175B (zh) * 2024-10-15 2026-03-17 广东药科大学 一类新型酰基苯丙氨酸衍生物、其制备方法及其作为药物的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10509463A (ja) * 1995-09-19 1998-09-14 セルラー サイエンセズ インコーポレイテッド 炎症反応に起因する哺乳類の疾病の治療方法およびその組成物
WO2012054528A2 (en) * 2010-10-19 2012-04-26 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1159146A (zh) * 1995-07-26 1997-09-10 弗门尼舍有限公司 风味产品及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10509463A (ja) * 1995-09-19 1998-09-14 セルラー サイエンセズ インコーポレイテッド 炎症反応に起因する哺乳類の疾病の治療方法およびその組成物
WO2012054528A2 (en) * 2010-10-19 2012-04-26 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOTECHNOLOGY AND BIOENGINEERING, vol. 118, JPN7026001460, 19 March 2021 (2021-03-19), pages 3395 - 3408, ISSN: 0005831980 *
PNAS, vol. Vol.112(21), JPN7026001459, 2015, pages 6601 - 6606, ISSN: 0005831979 *

Also Published As

Publication number Publication date
CN117769414A (zh) 2024-03-26
WO2022235557A1 (en) 2022-11-10
US20240189266A1 (en) 2024-06-13
EP4313297A4 (en) 2024-09-18
EP4313297A1 (en) 2024-02-07
KR20240006050A (ko) 2024-01-12
AU2022271191A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
JP2024516969A (ja) 代謝性疾患の治療のためのラクトイルアミノ酸
Cuadrado et al. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
Hellmich et al. The therapeutic potential of cystathionine β-synthetase/hydrogen sulfide inhibition in cancer
Pinto et al. Pharmacological modulation of ion channels for the treatment of cystic fibrosis
Jones et al. Inhibition of acetyl-CoA carboxylase 1 (ACC1) and 2 (ACC2) reduces proliferation and de novo lipogenesis of EGFRvIII human glioblastoma cells
Labbé et al. mTORC1 is required for brown adipose tissue recruitment and metabolic adaptation to cold
Zhang et al. Uncarboxylated osteocalcin ameliorates hepatic glucose and lipid metabolism in KKAy mice via activating insulin signaling pathway
Fan et al. Quercetin reduces cortical GABAergic transmission and alleviates MK-801-induced hyperactivity
Huang et al. M2 macrophages secrete glutamate-containing extracellular vesicles to alleviate osteoporosis by reshaping osteoclast precursor fate
Ma et al. Histone deacetylase inhibitor phenylbutyrate exaggerates heart failure in pressure overloaded mice independently of HDAC inhibition
Tirodkar et al. Expression of ceramide synthase 6 transcriptionally activates acid ceramidase in a c-Jun N-terminal kinase (JNK)-dependent manner
Mao et al. Ferroptosis: a potential bridge linking gut microbiota and chronic kidney disease
Li et al. Functional significance of gain-of-function H19 lncRNA in skeletal muscle differentiation and anti-obesity effects
Xu et al. Low expression of the intestinal metabolite butyric acid and the corresponding memory pattern regulate HDAC4 to promote apoptosis in rat hippocampal neurons
Wang et al. Histone β‐hydroxybutyrylation is critical in reversal of sarcopenia
Zheng et al. Carbon monoxide-releasing molecules reverse leptin resistance induced by endoplasmic reticulum stress
Xu et al. Diallyl trisulfide, a H2S donor, inhibits cell growth of human papillary thyroid carcinoma KTC‐1 cells through a positive feedback loop between H2S and cystathionine‐gamma‐lyase
Lim et al. Muscle miR-16 deletion results in impaired insulin sensitivity and contractile function in a sex-dependent manner
Zhou et al. Targeting gut S. aureofaciens Tü117 serves as a new potential therapeutic intervention for the prevention and treatment of hypertension
Guo et al. Exercise training improves cardiac function and regulates myocardial mitophagy differently in ischaemic and pressure‐overload heart failure mice
Jang et al. Free essential amino acid feeding improves endurance during resistance training via DRP1‐dependent mitochondrial remodelling
Africano et al. Identification of a histone deacetylase inhibitor as a therapeutic candidate for congenital central hypoventilation syndrome
Barazzoni et al. High-fat diet with acyl-ghrelin treatment leads to weight gain with low inflammation, high oxidative capacity and normal triglycerides in rat muscle
Qi et al. How to explain exercise-induced phenotype from molecular data: rethink and reconstruction based on AMPK and mTOR signaling
La Spina et al. Multiple mechanisms converging on transcription factor EB activation by the natural phenol pterostilbene

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250416

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260402